Onasemnogene abeparvovec for spinal muscular atrophy: The costlier drug ever
The US Food and Drug Administration (FDA) on May 24, 2019 approved onasemnogene abeparvovec, a drug for the treatment of spinal muscular atrophy (SMA). The drug, developed by the Swiss drugmaker Novartis, has been marketed under the trade name Zolgensma. The drug has been approved to be used in chil...
Saved in:
| 主要作者: | |
|---|---|
| 格式: | Editorial |
| 语言: | 英语 |
| 出版: |
2019
|
| 在线阅读: | https://doi.org/10.4103/ijabmr.ijabmr_190_19 |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|